Allogene Therapeutics Inc (ALLO)

Precedente Chiudi:

$2.76

Aprire:

$2.79

Volume 24 ore:

238.46K

Capitalizzazione di mercato:

$471.20M

Reddito:

$95,000

Utile/perdita netta:

$-327.27M

Rapporto P/E:

-1.1939

EPS:

-2.45

Flusso di cassa netto:

$-239.25M

1 W Prestazione:

-2.95%

1M Prestazione:

-23.13%

6M Prestazione:

+20.71%

1 anno Prestazione:

-52.03%

Intervallo 1D:

$2.79

$2.945

Portata 52W:

$2.23

$6.89

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Nome

Allogene Therapeutics Inc

Settore

Healthcare (1222)

Industria

Biotechnology (699)

Telefono

415-640-5325

Indirizzo

210 East Grand Avenue, South San Francisco

Dipendente

90

Cinguettio

@AllogeneTx

Prossima data di guadagno

2024-06-05

Ultimi documenti SEC

ALLO's Discussions on Twitter

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-05	Downgrade	Guggenheim	Buy → Neutral
2024-01-05	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-08	Iniziato	Citigroup	Buy
2023-06-26	Ripresa	Oppenheimer	Outperform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-01-24	Aggiornamento	JP Morgan	Neutral → Overweight
2023-01-06	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-12-12	Downgrade	BofA Securities	Buy → Underperform
2022-08-10	Downgrade	Raymond James	Outperform → Mkt Perform
2022-07-15	Aggiornamento	Goldman	Neutral → Buy
2022-06-03	Iniziato	Robert W. Baird	Neutral
2022-02-28	Reiterato	B. Riley Securities	Buy
2021-10-20	Iniziato	Cowen	Outperform
2021-10-08	Downgrade	Goldman	Buy → Neutral
2021-10-08	Downgrade	Stifel	Buy → Hold
2021-09-23	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-21	Ripresa	Jefferies	Buy
2021-05-20	Aggiornamento	Truist	Hold → Buy
2021-05-14	Iniziato	B. Riley Securities	Buy
2021-01-26	Aggiornamento	Stifel	Hold → Buy
2020-12-10	Ripresa	H.C. Wainwright	Buy
2020-11-24	Iniziato	BofA Securities	Buy
2020-10-23	Iniziato	RBC Capital Mkts	Outperform
2020-06-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-05-29	Reiterato	H.C. Wainwright	Buy
2020-05-19	Aggiornamento	ROTH Capital	Neutral → Buy
2020-05-15	Aggiornamento	Guggenheim	Neutral → Buy
2020-05-14	Reiterato	H.C. Wainwright	Buy
2020-05-14	Downgrade	SunTrust	Buy → Hold
2020-04-13	Iniziato	SunTrust	Buy
2020-03-13	Iniziato	H.C. Wainwright	Buy
2020-03-05	Iniziato	Stifel	Hold
2020-02-24	Iniziato	Berenberg	Hold
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-11-04	Iniziato	Canaccord Genuity	Buy
2019-08-09	Iniziato	BTIG Research	Buy
2019-06-05	Iniziato	ROTH Capital	Neutral
2019-05-31	Iniziato	Guggenheim	Neutral
2019-05-23	Iniziato	Stifel	Hold
2019-03-29	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie

CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?

Zacks Investment Research

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

GlobeNewswire Inc.

Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari

Allogene Therapeutics Inc (ALLO) Reddito 2024

Allogene Therapeutics Inc (ALLO) Reddito netto 2024

Allogene Therapeutics Inc (ALLO) Flusso di cassa 2024

Allogene Therapeutics Inc (ALLO) Utile per azione 2024

Allogene Therapeutics Inc Azioni (ALLO) insider trading